Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Ritonavir price increase: what are the consequences in 2004?

Published
18 December 2003
By
Keith Alcorn
More bad news on tenofovir/abacavir/3TC

Replacing a suppressive anti-HIV regimen with tenofovir/abacavir/3TC is a risky strategy according to a small, retrospective study published in The Lancet this week. Dutch researchers identified

Published
16 December 2003
By
Megan Nicholson
Better clinical outcomes if HAART started before CD4 cell count falls below 200

Individuals who start HAART when their CD4 cell count is below 200 cells/mm3 are more likely to progress to AIDS or death than patients who

Published
15 December 2003
By
Michael Carter
Landmark study shows why AZT/3TC/efavirenz now preferred as first-line HIV treatment

The combination of AZT, 3TC and efavirenz proved more durable than two initial HAART combinations composed of four drugs, and outclassed all combinations based on

Published
12 December 2003
By
Michael Carter
Fibre-, protein-, calorie-rich diet appears to protect against central fat gain in men

A diet rich in fibre, high in protein and providing plenty of calories appears to be protective against gaining central visceral fat (lipohypertrophy) in men,

Published
11 December 2003
By
Edwin J. Bernard
Different resistance patterns seen with subtype C HIV in Brazil

Treatment of people infected with HIV B and non-B subtypes in southern Brazil has shown that viral subtype influences likely resistance mutations, according to a

Published
11 December 2003
By
Megan Nicholson
Minority can have CD4 rises and no illness for more than 3 years after treatment failure

People with a stable low detectable viral load who continue with existing treatment continue to have rising CD4 cell counts and no clinical progression for

Published
11 December 2003
By
Edwin J. Bernard
South African drug deal bring $140 a year treatment within reach of African nations

GlaxoSmithKline and Boehringer Ingelheim have conceded defeat in a long-running battle to preserve their antiretroviral drug patents in South Africa. Following a Competition Commission judgement

Published
10 December 2003
By
Keith Alcorn
Fat loss in all body regions most common form of lipodystrophy in women

Women with HIV are more likely to experience overall body fat loss, rather than peripheral fat loss combined with central fat gain, according to an

Published
08 December 2003
By
Liz Highleyman
Is lipodystrophy caused by the action of antiretroviral drugs in the brain?

Lipodystrophy could be caused by the effects of antiretroviral drugs on specific brain regions, according to a hypothesis presented by Dutch researchers in the November

Published
04 December 2003
By
Christopher Gadd

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.